SCHEMBL20201866

SCHEMBL20201866

CCOC(=O)/C=C/c1cccc(F)c1OC

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.51
KMT2A Q03164 3/20 0.51
KDM4E B2RXH2 3/20 0.51
NFE2L2 Q16236 2/20 0.49
ALDH1A1 P00352 2/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
CA12 O43570 1/20 0.46
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
CA7 P43166 1/20 0.46
CA9 Q16790 1/20 0.46
CA14 Q9ULX7 1/20 0.46
MAOB P27338 2/20 0.45
PPARG P37231 1/20 0.44
PPARA Q07869 1/20 0.44
CYP3A4 P08684 1/20 0.44
HPGD P15428 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
LMNA P02545 1/20 0.43
MAPT P10636 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4592982 0.84 NFE2L2 (0.69) MEN1KMT2AKDM4ENFE2L2ALDH1A1
SCHEMBL28567920 0.84 PTGS2 (0.50) MEN1KMT2AKDM4EALDH1A1L3MBTL1
SCHEMBL28567922 0.84 PTGS2 (0.50) MEN1KMT2AKDM4EALDH1A1L3MBTL1
SCHEMBL1268397 0.84 RAB9A (0.54) MEN1KMT2AKDM4ENFE2L2ALDH1A1
SCHEMBL1268400 0.84 RAB9A (0.54) MEN1KMT2AKDM4ENFE2L2ALDH1A1
SCHEMBL31408756 0.84 RAB9A (0.54) MEN1KMT2AKDM4ENFE2L2ALDH1A1
SCHEMBL6852962 0.84 CA12 (0.54) MEN1KMT2ANFE2L2ALDH1A1L3MBTL1
SCHEMBL31756312 0.83 CA12 (0.46) MEN1KMT2AKDM4ENFE2L2ALDH1A1
SCHEMBL16815249 0.81 NFE2L2 (0.54) KDM4ENFE2L2ALDH1A1CA1CA2
SCHEMBL29090911 0.81 KDM4E (0.57) KMT2AKDM4ENFE2L2MAOBSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10858344-B2 Hydantoin containing deoxyuridine triphosphatase inhibitors CV6 THERAPEUTICS (NI) LIMITED (GB) 2020-12-08 US disclosed
WO-2018098206-A1 HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS CV6 THERAPEUTICS (NI) LIMITED (GB) 2018-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10858344-B2 Hydantoin containing deoxyuridine triphosphatase inhibitors DUT, TYMP, DPYD MEN1 3845/4885KMT2A 1934/4885KDM4E 1424/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.